TP53 mutations that increase the stability and half-life of mutant proteins in cancer cells and enhance protein detection by IHC4,13,14 characterize a subgroup of biologically aggressive prostate cancers with high risk of progression after prostatectomy. Here, TP53 is linked to prostate carcinoma.